News Sentiment

IPSC sentiment intelligence

Century Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.25 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-7.4% over one week, +0.0% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -7.4% Price reacting lower
Trend fit Trend active 0.0% over four weeks
Fair value 23.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 43
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 9
TradingView 6
Investing.com 4
simplywall.st 4
Seeking Alpha 2
Investing News Network 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 14
Balance sheet 2
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Market source Direct company coverage

Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

Century Therapeutics (NASDAQ:IPSC) will present data on its CNTY-813 iPSC-derived islet replacement therapy for type 1 diabetes at two upcoming scientific congresses in September and October 2026. The therapy, engineered with Allo-Evasion™ 5.0, aims for durable engraftment withou

Tone
Positive 70/100
Event
Market update
Published
14 Jul 2026 10:40
Source
Market source
Investing News Network Direct company coverage

Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026

Century Therapeutics (NASDAQ: IPSC) announced that its CNTY-813 preclinical data abstracts have been accepted for oral presentations at two upcoming scientific congresses: the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan and the Breakt

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 18:40
Source
Investing News Network
Investing.com Direct company coverage

Century Therapeutics abstracts accepted for diabetes conferences

Century Therapeutics (NASDAQ: IPSC) announced that abstracts for its CNTY-813 therapy program for type 1 diabetes have been accepted for oral presentations at two upcoming diabetes conferences: the EASD 2026 and CRC 2026. The company is developing this induced pluripotent stem ce

Tone
Positive 60/100
Event
Market update
Published
09 Jul 2026 12:11
Source
Investing.com
Finviz Direct company coverage

IPSC - Century Therapeutics Inc Short Interest

This article provides a detailed overview of Century Therapeutics Inc. (IPSC) stock, including its latest closing price, market capitalization, financial performance metrics, and key insider and institutional ownership data. It also highlights short interest, stock performance ov

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 12:10
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Century Therapeutics, Inc. – NASDAQ:IPSC

This page provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC), specifically focusing on its price-to-sales forward metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials for investors.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 16:39
Source
TradingView
www.marketscreener.com Direct company coverage

Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell 2000 Value Benchmark

Century Therapeutics, Inc. (NasdaqCM: IPSC) has been included in the Russell 2000 Value Benchmark. The company, a biotechnology firm, focuses on developing allogeneic cell therapies for various diseases, including solid tumors, hematological malignancies, and autoimmune condition

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 15:15
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Century Therapeutics, Inc.(NasdaqCM: IPSC) added to Russell Microcap Index

Century Therapeutics, Inc. (NasdaqCM: IPSC), a biotechnology company focused on allogeneic cell therapies, has been added to the Russell Microcap Index. The announcement highlights the company's progress in developing treatments for solid tumor and hematological malignancies, as

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 06:10
Source
www.marketscreener.com
TradingView Direct company coverage

Century Therapeutics, Inc. Actuals & Estimates (NASDAQ:IPSC)

This article provides an overview of Century Therapeutics, Inc. (NASDAQ: IPSC) stock, including its current price, performance trends, analyst forecasts, and financial data. It details the company's market capitalization, earnings, revenue, and EBITDA, while also offering guidanc

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:08
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Century Therapeutics, Inc. – NASDAQ:IPSC

This article provides financial information for Century Therapeutics, Inc. (NASDAQ: IPSC) on TradingView. It specifically highlights the company's enterprise value to EBIT forward. The content is primarily a financial data page from TradingView.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Century Therapeutics, Inc. – NASDAQ:IPSC

This article provides a brief financial overview of Century Therapeutics, Inc. (NASDAQ: IPSC) specifically focusing on its forward price-to-earnings ratio. It indicates that as of the market close, there were no trades recorded for the company's stock. The content is primarily a

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Century Therapeutics, Inc. – NASDAQ:IPSC

This article provides forward-looking enterprise value to revenue data for Century Therapeutics, Inc. (NASDAQ: IPSC) sourced from TradingView. The financial data and market information are presented within the context of a market data platform.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:12
Source
TradingView
TradingKey Direct company coverage

Century Therapeutics Inc (IPSC) Financial Health: Profitability & Balance Sheet Analysis

Century Therapeutics Inc (IPSC) has a financial score of 8.26, ranking 53rd in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. Despite this, the company reported a 100% year-over-year decrease in its latest quarterl

Tone
Negative 41/100
Event
Market update
Published
19 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Century Therapeutics Inc (IPSC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Century Therapeutics Inc (IPSC), highlighting its current valuation score, P/E ratio, and market performance. The company has a current valuation score of 6.56, ranking 317 out of 388 in the Biotechnology & Medical Research industry,

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 06:40
Source
TradingKey
Investing.com Direct company coverage

Century Therapeutics amends chief scientific officer contract to part-time role

Century Therapeutics has amended its chief scientific officer, Dr. Chad Cowan's, employment agreement to a part-time role, reducing his annual salary to $296,150 while he remains eligible for a pro-rated performance-based bonus. This move comes as the company, whose stock has sur

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jun 2026 21:40
Source
Investing.com
Stock Titan Direct company coverage

Century Therapeutics (IPSC) shifts Chief Scientific Officer to part-time role with new pay terms

Century Therapeutics (IPSC) has updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., transitioning him to a part-time role. Under the new agreement, Dr. Cowan's annual salary will be $296,150, and he will remain eligible for a pro-rated performance-ba

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 19:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com

Gregory Russotti, Chief Technology and Manufacturing Officer at Century Therapeutics (NASDAQ: IPSC), sold 2,584 shares of company stock worth $5,767 on June 12, 2026. This transaction was automatic and intended to cover tax withholding obligations related to restricted stock unit

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 08:10
Source
Investing.com Nigeria
Investing.com Australia Direct company coverage

Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com

Douglas Carr, SVP of Finance & Operations at Century Therapeutics (NASDAQ:IPSC), sold 1,654 shares worth $3,691 to cover tax withholding related to restricted stock unit vesting. The company's stock is up nearly 300% over the past year, and it recently presented positive preclini

Tone
Negative 40/100
Event
Market update
Published
16 Jun 2026 01:10
Source
Investing.com Australia
Stock Titan Direct company coverage

Tax-related share sale by Century Therapeutics (IPSC) SVP Carr

Douglas Carr, Senior Vice President of Finance and Operations at Century Therapeutics (IPSC), automatically sold 1,654 shares of common stock at $2.232 per share on June 12, 2026. This transaction was conducted to cover tax withholding obligations associated with the vesting of r

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding

Century Therapeutics executive Gregory Russotti sold 2,584 shares of common stock at an average price of $2.232 to cover tax withholding obligations related to restricted stock unit vesting. These sales were automatic and not at Russotti's discretion. After the transaction, he di

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings

Century Therapeutics' Chief Scientific Officer, Chad Cowan, reported a routine share activity where 358 common shares were withheld at $2.24 each to cover tax obligations following the vesting of restricted stock units. This was not an open-market sale. After this transaction, Co

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting

Century Therapeutics' President and CEO, Brent Pfeiffenberger, reported a tax-related disposition of 13,849 shares of Common Stock. These shares, valued at $2.24 each, were withheld by the company to satisfy tax obligations upon the vesting of restricted stock units (RSUs). This

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 00:10
Source
Stock Titan
Investing.com Direct company coverage

Century Therapeutics SVP Carr sells $3,691 in company stock

Douglas Carr, SVP of Finance & Operations at Century Therapeutics, Inc. (NASDAQ: IPSC), sold 1,654 shares of company stock worth $3,691 on June 12, 2026. The sale was executed to cover tax withholding obligations related to restricted stock units. After the transaction, Carr dire

Tone
Positive 66/100
Event
Market update
Published
15 Jun 2026 23:39
Source
Investing.com
Stock Titan Direct company coverage

Century Therapeutics (IPSC) director receives grant of 74,000 stock options

Century Therapeutics director Martin Patrick Murphy was granted 74,000 stock options with an exercise price of $2.24 per share, expiring on June 11, 2036. These options will vest on June 11, 2027, or the next annual meeting of stockholders, contingent on his continued service. Th

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 21:09
Source
Stock Titan